OncoTherapy Science, Inc.
4564・Growth Market・Pharmaceuticals
Governance
The company has adopted the corporate auditor system, with the board of directors comprising 5 members in total—3 internal and 2 outside directors (outside director ratio of 40%). The board holds regular meetings once a month, and a management oversight structure utilizing external experts such as attorneys and certified public accountants has been established.
Risk Management
Risks related to management strategy are analyzed and examined by the responsible departments and the director in charge, and deliberated by the Board of Directors as necessary. The Company receives advice from multiple experts, including lawyers, certified public accountants, patent attorneys, and outside researchers, and makes management decisions that incorporate sustainability-related risks.
Shareholder Returns
No dividend is currently paid. The policy is to prioritize securing R&D funding and to focus on retaining earnings internally. Continued advancement of R&D, including the Cancer Precision Medicine Business, is prioritized as a key issue, and no specific timing for dividend implementation has been indicated.
Dividend Policy
While recognizing shareholder returns as an important management priority, the company plans to prioritize internal retention of earnings for the time being in order to secure R&D funding for the continued execution of basic research, drug discovery research, and pharmaceutical development toward the launch of cancer treatment drugs. The body responsible for dividend decisions is the general shareholders' meeting. No dividends were paid during the fiscal year under review.
ESG
Sustainability initiatives are incorporated into the decision-making framework at the Board of Directors level. In terms of human resources, the company practices fair recruitment and promotion regardless of nationality or gender, and provides training tailored to each stage of research and development. While no specific numerical targets for personnel ratios have been set, the company intends to continue its policy of fair recruitment and promotion. No specific disclosures regarding climate change have been made.
Last updated: June 23, 2026